Progen Biotechnik Inks Deals for Assay Distribution, Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German firm Progen Biotechnik today announced an exclusive distribution agreement covering Germany with Asuragen to offer multiplexed assays based on Asuragen technology.

As a result of the deal, Progen can now offer assays incorporating Asuragen's Signature technology for the detection of mutations found in solid tumors, such as KRAS and BRAF, and fusion transcripts or mutations associated with specific leukemia types and subtypes, Progen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.